Dana-Farber Study Highlights the Need for Faster, More Accurate Diagnosis of Rare Cancer - Top-Institutions - MDSpire

Dana-Farber Study Highlights the Need for Faster, More Accurate Diagnosis of Rare Cancer

A new study from Dana-Farber Cancer Institute finds that patients with NUT carcinoma (NC), an aggressive squamous cell lung or head and neck cancer, often face delays in diagnosis—delays that can prevent them from receiving the right treatment or joining clinical trials.

  • By

  • December 8, 2025

  • 3 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Thoracic Oncology
    • Rare Cancers
    • Translational Cancer Research

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Thoracic Oncology
    • Rare Cancer Research
    • Molecular Pathology

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Thoracic Oncology
    • Head and Neck Cancers
    • Rare Cancer Clinical Trials

  • #4

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, MD

    Key Differentiators

    • Thoracic Oncology
    • Rare Cancer Diagnostics
    • Translational Research

Original Source(s)

Dana-Farber Study Highlights the Need for Faster, More Accurate Diagnosis of Rare Cancer

  • by

  • December 8, 2025

Related Content

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

Emerging applications of artificial intelligence for risk stratification in head and neck cancer: a scoping review